Recent News

• 03.31.2026 - Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
• 03.26.2026 - Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
• 03.23.2026 - HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
• 03.19.2026 - Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
• 03.10.2026 - Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
• 02.26.2026 - Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
• 02.24.2026 - Soligenix to Present at BIO Investment & Growth Summit
• 02.12.2026 - Soligenix Details Recent Progress and Upcoming Milestones
• 12.18.2025 - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
• 12.17.2025 - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Recent Filings

• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2026 - EX-99.1 EX-99.1
• 02.12.2026 - 8-K Current report
• 01.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.23.2026 - 8-K Current report
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities